Cargando…

Patient-Related Barriers to the Prescription of Cannabinoid-Based Medicines in Palliative Care: A Qualitative Approach

BACKGROUND: A minority of palliative care patients benefit from prescribed cannabinoid-based medicines (CBMs). OBJECTIVE: The objective of this study was to explore the perceptions, expectations, and experiences of CBM usage among palliative care patients and to evaluate whether and how they may con...

Descripción completa

Detalles Bibliográficos
Autores principales: Kalonji, Pauline, Revol, Aurélie, Broers, Barbara, Ljuslin, Michael, Pautex, Sophie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc., publishers 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9531874/
https://www.ncbi.nlm.nih.gov/pubmed/36203714
http://dx.doi.org/10.1089/pmr.2022.0021
_version_ 1784801994034118656
author Kalonji, Pauline
Revol, Aurélie
Broers, Barbara
Ljuslin, Michael
Pautex, Sophie
author_facet Kalonji, Pauline
Revol, Aurélie
Broers, Barbara
Ljuslin, Michael
Pautex, Sophie
author_sort Kalonji, Pauline
collection PubMed
description BACKGROUND: A minority of palliative care patients benefit from prescribed cannabinoid-based medicines (CBMs). OBJECTIVE: The objective of this study was to explore the perceptions, expectations, and experiences of CBM usage among palliative care patients and to evaluate whether and how they may constitute an obstacle to prescription. DESIGN: This is a qualitative study involving semistructured in-depth interviews with 10 patients hospitalized in a palliative care unit in Geneva, Switzerland. The data were analyzed using the interpretative phenomenological analysis method. RESULTS: Semistructured interviews were conducted on 10 patients (average age of 73.3 years), mainly with advanced cancer. Most patients favored CBM use in palliative care and distinguished it from recreational use. Seven themes were identified from patients' perceptions, experiences, and expectations during the interviews: right time to begin CBMs, off-label use, information about side effects, lack of a safe medical framework, costs, relatives, and social acceptance of CBMs. CONCLUSION: The obstacles described by the patients seem to be surmountable with specific measures at the clinical level. We suggest training health professionals in a palliative care setting, especially in explaining the effects and side effects. CBMs will undoubtedly play a more significant role in palliative care medicine in the years to come.
format Online
Article
Text
id pubmed-9531874
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Mary Ann Liebert, Inc., publishers
record_format MEDLINE/PubMed
spelling pubmed-95318742022-10-05 Patient-Related Barriers to the Prescription of Cannabinoid-Based Medicines in Palliative Care: A Qualitative Approach Kalonji, Pauline Revol, Aurélie Broers, Barbara Ljuslin, Michael Pautex, Sophie Palliat Med Rep Original Article BACKGROUND: A minority of palliative care patients benefit from prescribed cannabinoid-based medicines (CBMs). OBJECTIVE: The objective of this study was to explore the perceptions, expectations, and experiences of CBM usage among palliative care patients and to evaluate whether and how they may constitute an obstacle to prescription. DESIGN: This is a qualitative study involving semistructured in-depth interviews with 10 patients hospitalized in a palliative care unit in Geneva, Switzerland. The data were analyzed using the interpretative phenomenological analysis method. RESULTS: Semistructured interviews were conducted on 10 patients (average age of 73.3 years), mainly with advanced cancer. Most patients favored CBM use in palliative care and distinguished it from recreational use. Seven themes were identified from patients' perceptions, experiences, and expectations during the interviews: right time to begin CBMs, off-label use, information about side effects, lack of a safe medical framework, costs, relatives, and social acceptance of CBMs. CONCLUSION: The obstacles described by the patients seem to be surmountable with specific measures at the clinical level. We suggest training health professionals in a palliative care setting, especially in explaining the effects and side effects. CBMs will undoubtedly play a more significant role in palliative care medicine in the years to come. Mary Ann Liebert, Inc., publishers 2022-09-16 /pmc/articles/PMC9531874/ /pubmed/36203714 http://dx.doi.org/10.1089/pmr.2022.0021 Text en © Pauline Kalonji et al., 2022; Published by Mary Ann Liebert, Inc. https://creativecommons.org/licenses/by/4.0/This Open Access article is distributed under the terms of the Creative Commons License [CC-BY] (http://creativecommons.org/licenses/by/4.0 (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Kalonji, Pauline
Revol, Aurélie
Broers, Barbara
Ljuslin, Michael
Pautex, Sophie
Patient-Related Barriers to the Prescription of Cannabinoid-Based Medicines in Palliative Care: A Qualitative Approach
title Patient-Related Barriers to the Prescription of Cannabinoid-Based Medicines in Palliative Care: A Qualitative Approach
title_full Patient-Related Barriers to the Prescription of Cannabinoid-Based Medicines in Palliative Care: A Qualitative Approach
title_fullStr Patient-Related Barriers to the Prescription of Cannabinoid-Based Medicines in Palliative Care: A Qualitative Approach
title_full_unstemmed Patient-Related Barriers to the Prescription of Cannabinoid-Based Medicines in Palliative Care: A Qualitative Approach
title_short Patient-Related Barriers to the Prescription of Cannabinoid-Based Medicines in Palliative Care: A Qualitative Approach
title_sort patient-related barriers to the prescription of cannabinoid-based medicines in palliative care: a qualitative approach
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9531874/
https://www.ncbi.nlm.nih.gov/pubmed/36203714
http://dx.doi.org/10.1089/pmr.2022.0021
work_keys_str_mv AT kalonjipauline patientrelatedbarrierstotheprescriptionofcannabinoidbasedmedicinesinpalliativecareaqualitativeapproach
AT revolaurelie patientrelatedbarrierstotheprescriptionofcannabinoidbasedmedicinesinpalliativecareaqualitativeapproach
AT broersbarbara patientrelatedbarrierstotheprescriptionofcannabinoidbasedmedicinesinpalliativecareaqualitativeapproach
AT ljuslinmichael patientrelatedbarrierstotheprescriptionofcannabinoidbasedmedicinesinpalliativecareaqualitativeapproach
AT pautexsophie patientrelatedbarrierstotheprescriptionofcannabinoidbasedmedicinesinpalliativecareaqualitativeapproach